Characterization of RO4583298 as a novel potent, dual antagonist with in vivo activity at tachykinin NK(1) and NK(3) receptors

BACKGROUND AND PURPOSE: Clinical results of osanetant and talnetant (selective-NK(3) antagonists) indicate that blocking the NK(3) receptor could be beneficial for the treatment of schizophrenia. The objective of this study was to characterize the in vitro and in vivo properties of a novel dual NK(1...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Main Authors: Malherbe, P, Knoflach, F, Hernandez, MC, Hoffmann, T, Schnider, P, Porter, RH, Wettstein, JG, Ballard, TM, Spooren, W, Steward, L
Formato: Artigo
Idioma:Inglês
Publicado em: Blackwell Publishing Ltd 2011
Assuntos:
Research Papers
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC3042203/
https://ncbi.nlm.nih.gov/pubmed/21039418
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/j.1476-5381.2010.01096.x
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados